ASCO 2024 | EVEREST-2: A2B694, a CAR-T cell therapy, in MSLN-expressing solid tumors
Salman Punekar, MD, NYU Langone, New York, NY, gives an overview of the Phase I/II EVEREST-2 trial (NCT06051695) of A2B694 in patients with recurrent unresectable, locally advanced, or metastatic solid tumors including ovarian, lung and gastrointestinal cancers. A2B694 is a logic-gated Tmod CAR CAR-T cell targeting mesothelin (MSLN)-expressing solid tumors exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding – Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
